BrainStorm Cell Therapeutics Inc.

463 articles about BrainStorm Cell Therapeutics Inc.

• 

  BioSpace Movers & Shakers, April 3

  4/3/2020

  Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.

• David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer

  4/1/2020

  International Pharmaceutical Veteran to Lead Global Business and Commercial Development

• BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors

  3/31/2020

  Prof. Frenkel, Chairman of the Group of Thirty (G-30) Board of Trustees, Former Chairman of JPMorgan Chase International and Former Governor of the Bank of Israel Joins the Board to Support the Company’s Global Expansion

• BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19

  3/16/2020

  Funding Secured and Senior Management Team Activated by CEO to Ensure Advancement of all Operational Activities and Completion of Corporate Clinical Milestones

• BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share

  3/6/2020

  BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC, a healthcare-focused family office based in Miami, Florida, in connection with a privately negotiated sale of common stock and  a warrant to purchase common stock (collectively, the “securities”).

• 

  Clinical Catch-Up: February 24-28

  3/2/2020

  The month of February ended with a flurry of clinical trial announcements. Here’s a look.

• Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial

  2/27/2020

  BrainStorm Cell Therapeutics Inc. announced that Partners MS Center at Brigham and Women’s Hospital, a leading research and clinical care center, has contracted with BrainStorm as a clinical study site for the Company’s Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn® in participants with progressive Multiple Sclerosis.

• BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 Conference Call and Webcast @ 8:00 a.m. Eastern Time Today

  2/18/2020

  BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended December 31, 2019.

• BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference

  2/17/2020

  BrainStorm Cell Therapeutics Inc. announced that Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, will provide a clinical update on the Company’s ALS and MS trials and present insights on the future growth strategy of BrainStorm at the Noble Capital Markets’ Sixteenth Annual Investor Conference, taking place February 16-18, 2020 at the Hard Rock Hotel & Casino, Hollywood, Florida.

• BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS

  2/11/2020

  BrainStorm Cell Therapeutics, Inc. announced that the Company recently held a high level meeting with the U.S. Food and Drug Administration to discuss potential NurOwn® regulatory pathways for approval in ALS.

• BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update

  2/10/2020

  BrainStorm Cell Therapeutics, Inc. announced that the Company will hold a conference call to update shareholders on financial results for the fourth quarter and full year ended December 31, 2019, and provide a corporate update, at 8:00 a.m., Eastern Time, on Tuesday, February 18, 2020.

• BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference

  2/4/2020

  BrainStorm Cell Therapeutics Inc. announced that Chaim Lebovits, CEO and President, will provide an update of the Company’s ALS and MS trials and company growth strategy at The BIO CEO & Investor Conference, being held February 10-11, 2020 at the New York Marriott Marquis.

• BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®

  1/29/2020

  BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the European Patent Office has communicated its intention to grant a European patent titled 'Methods of Generating Mesenchymal Stem Cells which secrete Neurotrophic Factors'.

• BrainStorm Cell Therapeutic’s COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit

  1/21/2020

  BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, will present at the 10th Annual California ALS Research Summit, January 24-25 at Cedars-Sinai Medical Center, Los Angeles, California. 

• BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week

  1/7/2020

  BrainStorm Cell Therapeutics Inc. announced that Chaim Lebovits, President and Chief Executive Officer, will provide a corporate overview at the 2020 Biotech Showcase, being held on January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

• NurOwn® Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue

  12/19/2019

  BrainStorm Cell Therapeutics, Inc. announced that the clinical trial independent Data Safety Monitoring Board has completed the first, pre-specified interim analysis, of safety outcomes for 9 participants enrolled in the Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn® in participants with progressive Multiple Sclerosis.

• BrainStorm Issues 2019 Letter to Shareholders

  12/18/2019

  BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapeutics for neurodegenerative diseases, issued a Letter to Shareholders.

• BrainStorm Selected as Buzz of BIO 2020 Winner

  12/11/2019

  BrainStorm Cell Therapeutics Inc. announced, that it was selected as the Buzz of BIO, in the Public Therapeutics Biotech category, and due to extensive voter participation BrainStorm also received an invitation to make a complimentary company presentation at the BIO CEO & Investor Conference, to be held in New York City on February 10-11, 2020.

• BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND

  11/26/2019

  BrainStorm’s Chief Operating and Chief Medical Officer, Ralph Kern MD MHSc, will make a podium presentation at Clinical Trials Session

• 

  Clinical Catch-Up: November 18-22

  11/25/2019

  As usual, it was a busy week for clinical trial updates. Here’s a look.